Hua Medicine Limited   Report issue

For profit Phase 1 Phase 3
Founded: Shanghai China (2011)

Organization Overview

First Clinical Trial
2013
NCT01952535
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Hua Medicine Limited

Active Ingredients

Drugs in Phase 3 Trials (1)

dorzagliatin (14 trials)

Drugs in Phase 1 Trials (2)

empagliflozin (jardiance) (1 trial)

sitagliptin (januvia) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus (Phase 1)

Diabetes Mellitus, Type 2 (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 14
  • # of Trial APIs: 3